196 related articles for article (PubMed ID: 31933006)
21. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
22. Feeding Next-Generation Nanomedicines to Europe: Regulatory and Quality Challenges.
Musazzi UM; Franzè S; Condorelli F; Minghetti P; Caliceti P
Adv Healthc Mater; 2023 Dec; 12(30):e2301956. PubMed ID: 37718353
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
Dri DA; Rinaldi F; Carafa M; Marianecci C
Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
[TBL] [Abstract][Full Text] [Related]
24. Regulation of nanomedicines in the EU: distilling lessons from the pediatric and the advanced therapy medicinal products approaches.
Chowdhury N
Nanomedicine (Lond); 2010 Jan; 5(1):135-42. PubMed ID: 20025470
[TBL] [Abstract][Full Text] [Related]
25. The nanomedicines alliance: an industry perspective on nanomedicines.
Malinoski FJ
Nanomedicine; 2014 Nov; 10(8):1819-20. PubMed ID: 25038497
[TBL] [Abstract][Full Text] [Related]
26. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
Schiestl M; Zabransky M; Sörgel F
Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
[TBL] [Abstract][Full Text] [Related]
27. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
28. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
29. Advanced Health Technologies and Nanotechnologies in Neurodegenerative Diseases.
Naziris N; Demetzos C
Adv Exp Med Biol; 2021; 1339():317. PubMed ID: 35023119
[TBL] [Abstract][Full Text] [Related]
30. Development of Taiwan's strategies for regulating nanotechnology-based pharmaceuticals harmonized with international considerations.
Guo JW; Lee YH; Huang HW; Tzou MC; Wang YJ; Tsai JC
Int J Nanomedicine; 2014; 9():4773-83. PubMed ID: 25342901
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.
Bobo D; Robinson KJ; Islam J; Thurecht KJ; Corrie SR
Pharm Res; 2016 Oct; 33(10):2373-87. PubMed ID: 27299311
[TBL] [Abstract][Full Text] [Related]
32. The similarity question for biologicals and non-biological complex drugs.
Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
[TBL] [Abstract][Full Text] [Related]
33. Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Halwani AA
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057002
[TBL] [Abstract][Full Text] [Related]
34. Policy challenges of nanomedicine for Australia's PBS.
Faunce TA
Aust Health Rev; 2009 May; 33(2):258-67. PubMed ID: 19563314
[TBL] [Abstract][Full Text] [Related]
35. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?
Emily M; Ioanna N; Scott B; Beat F
AAPS J; 2018 Aug; 20(5):92. PubMed ID: 30128758
[TBL] [Abstract][Full Text] [Related]
36. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
37. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
Di Francesco T; Sublet E; Borchard G
Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
[TBL] [Abstract][Full Text] [Related]
38. How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries.
Sofia N; Mühlebach S; Musazzi UM; Khatib R; Martinez Sesmero JM; Lipp HP; Surugue J; Di Francesco T; Flühmann B
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371701
[TBL] [Abstract][Full Text] [Related]
39. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
Urbán P; Liptrott NJ; Bremer S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
[TBL] [Abstract][Full Text] [Related]
40. Personalized Nanomedicine: A Revolution at the Nanoscale.
Fornaguera C; García-Celma MJ
J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
